IGM Biosciences Overview

  • Year Founded
  • 1993

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 16

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $78M

IGM Biosciences General Information

Description

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Contact Information

Website
www.igmbio.com
Formerly Known As
Palingen, Inc.
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 325 East Middlefield Road
  • Mountain View, CA 94043
  • United States
+1 (650)
Primary Industry
Drug Discovery
Parent Company
Concentra Biosciences
Vertical(s)
Corporate Office
  • 325 East Middlefield Road
  • Mountain View, CA 94043
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

IGM Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 14-Aug-2025 $78M Completed Generating Revenue
6. PIPE 22-Jun-2023 Completed Generating Revenue
5. IPO 18-Sep-2019 Completed Generating Revenue
4. Later Stage VC (Series C) 08-Jul-2019 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series B1) 23-Mar-2012 Completed Clinical Trials - Phase 1
2. Later Stage VC (Series B) 16-Jul-2010 $1.3M $2.8M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 25-Aug-1993 $1.5M $1.5M Completed Product Development
To view IGM Biosciences’s complete valuation and funding history, request access »

IGM Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-1
Series B
Series A 3,060,000 $0.010000 $0.04 $0.5 $0.5 1x $0.5 10.71%
To view IGM Biosciences’s complete cap table history, request access »

IGM Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment
Drug Discovery
Mountain View, CA
16 As of 2025

Boston, MA
 

Santa Monica, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

IGM Biosciences Competitors (57)

One of IGM Biosciences’s 57 competitors is Compass Therapeutics, a Formerly VC-backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Compass Therapeutics Formerly VC-backed Boston, MA
Kite Pharma Formerly VC-backed Santa Monica, CA
Mustang Bio Formerly VC-backed Waltham, MA
Instil Bio Formerly VC-backed Dallas, TX
Allogene Therapeutics Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 57 competitors. Get the full list »

IGM Biosciences Patents

IGM Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026072101-A1 Method for purifying biomixtures Pending 27-Sep-2024
WO-2025117221-A1 Multimeric anti-respiratory syncytial virus binding molecule Inactive 27-Nov-2023
WO-2024229151-A2 Multimeric coronavirus binding molecules and uses thereof Inactive 02-May-2023
WO-2024229151-A3 Multimeric coronavirus binding molecules and uses thereof Inactive 02-May-2023
US-20260347469-A1 T cell costimulatory multimeric binding molecules and uses thereof Pending 06-Jan-2023 C07K16/2809
To view IGM Biosciences’s complete patent history, request access »

IGM Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

IGM Biosciences Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Baker Brothers Investments Hedge Fund Minority
Janus Henderson Investors Asset Manager Minority
Redmile Group Venture Capital Minority
Topsoe PE-Backed Company Minority
Vivo Capital Venture Capital Minority
To view IGM Biosciences’s complete investors history, request access »

IGM Biosciences ESG

Risk Overview

Risk Rating

Updated September, 30, 2025

41.15 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,271

Rank

Percentile

Pharmaceuticals

Industry

of 908

Rank

Percentile

Pharmaceuticals

Subindustry

of 406

Rank

Percentile

To view IGM Biosciences’s complete esg history, request access »

IGM Biosciences FAQs

  • When was IGM Biosciences founded?

    IGM Biosciences was founded in 1993.

  • Where is IGM Biosciences headquartered?

    IGM Biosciences is headquartered in Mountain View, CA.

  • What is the size of IGM Biosciences?

    IGM Biosciences has 16 total employees.

  • What industry is IGM Biosciences in?

    IGM Biosciences’s primary industry is Drug Discovery.

  • Is IGM Biosciences a private or public company?

    IGM Biosciences is a Private company.

  • What is the current valuation of IGM Biosciences?

    The current valuation of IGM Biosciences is .

  • What is IGM Biosciences’s current revenue?

    The current revenue for IGM Biosciences is .

  • How much funding has IGM Biosciences raised over time?

    IGM Biosciences has raised $317M.

  • Who are IGM Biosciences’s investors?

    Baker Brothers Investments, Janus Henderson Investors, Redmile Group, Topsoe, and Vivo Capital have invested in IGM Biosciences.

  • Who are IGM Biosciences’s competitors?

    Compass Therapeutics, Kite Pharma, Mustang Bio, Instil Bio, and Allogene Therapeutics are some of the 57 competitors of IGM Biosciences.

  • When was IGM Biosciences acquired?

    IGM Biosciences was acquired on 14-Aug-2025.

  • Who acquired IGM Biosciences?

    IGM Biosciences was acquired by Concentra Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process